At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
INCB018424drug
Likely dose
INCB018424 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of INCB018424 in Patients With Advanced Hematologic Malignancies
In Brief
A Phase 2 clinical trial evaluating INCB018424 for Acute Myeloid Leukemia and 3 related conditions. Completed, enrolled 51 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if ruxolitinib can help to control advanced hematological malignancies. The safety of this drug will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia
CountriesUnited States
CollaboratorsIncyte Corporation
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2008
Enrollment StartMay 2008
Primary CompletionMar 2017
TodayJul 2026
First PostedMay 7, 2008
Enrollment StartMay 12, 2008
Primary CompletionMar 23, 2017
TodayJul 2, 2026
Enrollment to primary: 8.9 yearsPosted 18.2 years ago
Interventions
INCB018424drug
Starting dose: 25 mg by mouth (po) twice daily for 7 days each week for 4 weeks.